Novel epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, pharmaceutical compositions including same and their use in the treatment of EGFR-TK related diseases or disorders are disclosed. Novel radiolabeled EGFR-TK inhibitors as their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are further disclosed. The disclosed EGFR-TK inhibitors comprise a polyalkylene glycol moiety and/or a hydroxy-containing moiety and are characterized by improved solubility, biostability and bioavailability. Processes of preparing the disclosed EGFR-TK inhibitors and of radiolabeling same, via, for example, one-step radiosyntheses, are also disclosed.
本发明揭示了新型
表皮生长因子受体
酪氨酸激酶(
EGFR-TK)
抑制剂,包括同样的药物组合物及其在治疗
EGFR-TK相关疾病或疾病中的应用。进一步揭示了新型放射性标记的
EGFR-TK
抑制剂,以及它们作为医学放射成像(如正电子发射断层扫描(PET)和单光子发射计算机断层扫描(
SPECT))的
生物标记物的应用,以及作为放射性药物用于放射治疗。所揭示的
EGFR-TK
抑制剂包括聚烷基醚基团和/或含羟基的基团,并具有改善的溶解性、
生物稳定性和
生物利用度。还揭示了制备所述
EGFR-TK
抑制剂和放射性标记同样的过程,例如一步放射合成。